Drug intelligence / Profile preview

anti-Siglec-E antibody

Development stage
Preclinical
Lead developer
University Hospital Basel
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Parenteral
01

Overview

Anti-Siglec-E antibody is a monoclonal antibody that targets Sialic acid-binding Ig-like lectin E (Siglec-E), an inhibitory receptor found on murine myeloid cells, including microglia and macrophages. Siglec-E is the mouse functional homolog of human Siglec-9 and serves as an innate immune checkpoint. It recognizes sialic acid ligands on the surface of cells; in the tumor microenvironment, cancer cells exploit this interaction to evade immune clearance by sending 'don't eat me' signals. By blocking the Siglec-E receptor, the antibody prevents these inhibitory signals, thereby promoting the phagocytosis of tumor cells by microglia. Research, such as that presented by the University Hospital Basel, utilizes anti-Siglec-E antibodies in preclinical models of glioblastoma to investigate the therapeutic potential of targeting the sialic acid-Siglec axis to enhance anti-tumor innate immunity.

Other names
anti-Siglec-ESiglec-E antibody
02

Targets

Siglec-E (Sialic acid-binding immunoglobulin-like lectin E)

Beyond the preview

Go deeper on anti-Siglec-E antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-Siglec-E antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call